6 Result(s)

Article

Impact of rituximab on COVID-19 outcomes

Rituximab is associated with prolonged B-cell depletion and secondary hypogammaglobulinemia and is associated with a dampened humoral response and increased infectious complications. To describe the potential ...

Hannah Levavi, Guido Lancman, Janice Gabrilove in Annals of Hematology (2021)

Article

Plasma hemoglobin in COVID-19: authors’ reply

Guido Lancman, Bridget K. Marcellino, Santiago Thibaud, Kevin Troy in Annals of Hematology (2021)

Article

Coombs-negative hemolytic anemia and elevated plasma hemoglobin levels in COVID-19

Guido Lancman, Bridget K. Marcellino, Santiago Thibaud, Kevin Troy in Annals of Hematology (2021)

Article

Targeting Nuclear Export Proteins in Multiple Myeloma Therapy

Multiple myeloma (MM) is an incurable malignancy of plasma cells with a clinical course characterized by multiple relapses and treatment refractoriness. While recent treatment advancements have extended overal...

Nicholas Theodoropoulos, Guido Lancman, Ajai Chari in Targeted Oncology (2020)

Article

Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia

SARS-CoV-2 has infected millions of people worldwide, but little is known at this time about second infections or reactivation. Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B c...

Guido Lancman, John Mascarenhas, Michal Bar-Natan in Journal of Hematology & Oncology (2020)